FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015607590> ?p ?o ?g. }

• W2015607590 endingPage "747" @default.
• W2015607590 startingPage "737" @default.
• W2015607590 abstract "Connective tissue growth factor (CTGF), a downstream mediator of transforming growth factor-β1, mediates mesangial cell/fibroblast proliferation and extracellular matrix production by renal cells. Here, we show that renal tubular epithelial cells from patients with minimal change nephritic syndrome produced CTGF after glucocorticoid treatment. In addition, the glucocorticoid dexamethasone (DEX) increased CTGF mRNA levels in the kidneys of C57B6 but not SJL mice and produced intermediate CTGF mRNA levels in the kidneys of F1 (C57B6 × SJL) mice, midway between the levels found for parental strains. DEX also increased CTGF mRNA levels in cultured tubular epithelial cells derived from C57B6 (mProx24) but not SJL (MCT) mice via transcriptional up-regulation of CTGF mRNA. Transient transfection experiments using luciferase reporter constructs bearing CTGF promoter fragments revealed that the −897- to −628-bp fragment contained DEX-responsive positive regulatory elements, which were active in mProx24 but not MCT cells. Long-term DEX treatment resulted in fibronectin deposition in the kidneys of C57B6 but not SJL mice, and this effect was inhibited by co-administration of CTGF anti-sense oligodeoxynucleotides. Thus, glucocorticoid-induced renal fibrogenesis seems to be influenced by genetic background, with the critical DEX-responsive elements in the −897- to −628-bp region of the CTGF promoter. Connective tissue growth factor (CTGF), a downstream mediator of transforming growth factor-β1, mediates mesangial cell/fibroblast proliferation and extracellular matrix production by renal cells. Here, we show that renal tubular epithelial cells from patients with minimal change nephritic syndrome produced CTGF after glucocorticoid treatment. In addition, the glucocorticoid dexamethasone (DEX) increased CTGF mRNA levels in the kidneys of C57B6 but not SJL mice and produced intermediate CTGF mRNA levels in the kidneys of F1 (C57B6 × SJL) mice, midway between the levels found for parental strains. DEX also increased CTGF mRNA levels in cultured tubular epithelial cells derived from C57B6 (mProx24) but not SJL (MCT) mice via transcriptional up-regulation of CTGF mRNA. Transient transfection experiments using luciferase reporter constructs bearing CTGF promoter fragments revealed that the −897- to −628-bp fragment contained DEX-responsive positive regulatory elements, which were active in mProx24 but not MCT cells. Long-term DEX treatment resulted in fibronectin deposition in the kidneys of C57B6 but not SJL mice, and this effect was inhibited by co-administration of CTGF anti-sense oligodeoxynucleotides. Thus, glucocorticoid-induced renal fibrogenesis seems to be influenced by genetic background, with the critical DEX-responsive elements in the −897- to −628-bp region of the CTGF promoter. Connective tissue growth factor (CTGF) is a member of the CTGF, cyr 61/cef 10, nov (CCN) protein family, which participates in a wide variety of biological processes such as embryonic development and tissue repair.1Moussad EE Brigstock DR Connective tissue growth factor: what's in a name?.Mol Genet Metab. 2000; 71: 276-292Crossref PubMed Scopus (441) Google Scholar, 2Takigawa M CTGF/Hcs24 as a multifunctional growth factor for fibroblasts, chondrocytes and vascular endothelial cells.Drug News Perspect. 2003; 16: 11-21Crossref PubMed Scopus (77) Google Scholar CTGF itself is a potent and ubiquitously expressed growth factor for fibroblasts, chondrocytes and vascular endothelial cells.2Takigawa M CTGF/Hcs24 as a multifunctional growth factor for fibroblasts, chondrocytes and vascular endothelial cells.Drug News Perspect. 2003; 16: 11-21Crossref PubMed Scopus (77) Google Scholar CTGF is also a downstream mediator of transforming growth factor (TGF)-β1, a key cytokine involved in renal fibrogenesis, ie, glomerulosclerosis and interstitial fibrosis. As such CTGF plays a unique role in mediating mesangial cell/fibroblast proliferation and extracellular matrix production by renal cells.3Blom IE Goldschmeding R Leask A Gene regulation of connective growth factor: new targets for antifibrotic therapy?.Matrix Biol. 2002; 21: 473-482Crossref PubMed Scopus (320) Google Scholar, 4Gupta S Clarkson MR Duggan J Brady HR Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis.Kidney Int. 2000; 58: 1389-1399Crossref PubMed Scopus (268) Google Scholar Glomerular visceral/parietal epithelial cells, mesangial cells, fibroblasts, and endothelial cells have been shown to produce CTGF in fibrosing kidneys.4Gupta S Clarkson MR Duggan J Brady HR Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis.Kidney Int. 2000; 58: 1389-1399Crossref PubMed Scopus (268) Google Scholar, 5Riser BL Denichilo M Cortes P Baker C Grondini JM Yee J Narins RG Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis.J Am Soc Nephrol. 2000; 11: 25-38Crossref PubMed Scopus (21) Google Scholar, 6Yokoi H Mukoyama M Nagae T Mori K Suganami T Sawai K Yoshioka T Koshikawa M Nishida T Takigawa M Sugawara A Nakao K Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis.J Am Soc Nephrol. 2004; 15: 1430-1440Crossref PubMed Scopus (221) Google Scholar We previously showed that tubular epithelial cells are potent producers of CTGF and that CTGF itself probably plays a role in renal fibrogenesis, as determined using the remnant kidney model.7Okada H Kikuta T Kobayashi T Inoue T Kanno Y Takigawa M Sugaya T Kopp JB Suzuki H Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis.J Am Soc Nephrol. 2005; 16: 133-143Crossref PubMed Scopus (169) Google Scholar, 8Inoue T Okada H Kobayashi T Watanabe Y Kanno Y Kopp JB Nishida T Takigawa M Ueno M Nakamura T Suzuki H Hepatocyte growth factor counteracts transforming growth factor-β1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice.FASEB J. 2003; 17: 268-270PubMed Google Scholar Minimal change nephrotic syndrome is a benign disease that rarely leads to renal failure.9Eddy AA Symons JM Nephrotic syndrome in childhood.Lancet. 2003; 362: 629-639Abstract Full Text Full Text PDF PubMed Scopus (596) Google Scholar Although its frequency remains to be clarified, however, minimal change nephrotic syndrome follows a steroid-dependent course, and relapsing patients sometimes develop renal functional impairment as a result of glomerulosclerosis and/or interstitial fibrosis that is thought to be attributable to long-term protein overload.10Remuzzi G Ruggenenti P Perico N Chronic renal diseases: renoprotective benefits of renin-angiotensin system inhibition.Ann Intern Med. 2002; 136: 604-615Crossref PubMed Scopus (239) Google Scholar As an alternative hypothesis, we proposed that these changes might be attributable to long-term exposure to glucocorticoids, which have been reported to be potent inducers of CTGF in the kidney.11Dammeier J Beer HD Brauchle M Werner S Dexamethasone is a novel potent inducer of connective tissue growth factor expression.J Biol Chem. 1998; 273: 18185-18190Crossref PubMed Scopus (126) Google Scholar In this study, we immunohistochemically analyzed human renal biopsy material and mouse kidneys to determine which kidney cells expressed CTGF in response to glucocorticoid treatment. Our results showed that glucocorticoid induced CTGF expression in tubular epithelial cells. We then examined the molecular mechanisms responsible for this effect using cultured mouse tubular epithelial cells. Finally, we determined whether glucocorticoid treatment itself induced renal fibrogenesis. Cultured mouse proximal tubular epithelial cell lines, mProx2412Takaya K Koya D Isono M Sugimoto T Sugaya T Kashiwagi A Haneda M Involvement of ERK pathway in albumin-induced MCP-1 expression in mouse proximal tubular cells.Am J Physiol. 2003; 284: F1037-F1045Crossref PubMed Scopus (104) Google Scholar and MCT,13Okada H Danoff TM Kalluri R Neilson EG Early role of Fsp1 in epithelial-mesenchymal transformation.Am J Physiol. 1997; 273: F563-F574PubMed Google Scholar derived from C57B6 and SJL mice, respectively, were maintained in Dulbecco's modified Eagle's medium containing 10% fetal calf serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. For experimental purposes, the cells were seeded in six-well plates (1 × 105 cells/well) and incubated overnight in growth medium, after which the medium was replaced with modified K-1 medium (50:50 Ham's F-12/Dulbecco's modified Eagle's medium with 5 μg/ml of transferrin and 5 μg/ml of insulin). After 48 hours, various doses of dexamethasone (DEX; Sigma, St. Louis, MO) or rhTGF-β1 (R&D Systems, Minneapolis, MN) were added to the wells, and the cells were harvested for mRNA extraction as described below after various incubation times. To examine the mechanism of DEX-induced CTGF expression in these cells, neutralizing anti-TGF-β (Genzyme Corp., Cambridge, MA) and anti-CTGF7Okada H Kikuta T Kobayashi T Inoue T Kanno Y Takigawa M Sugaya T Kopp JB Suzuki H Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis.J Am Soc Nephrol. 2005; 16: 133-143Crossref PubMed Scopus (169) Google Scholar antibodies, as well as rmTNF-α (10 ng/ml; R&D Systems), the AP-1 inhibitor curcumin (4.0 μmol/L; Sigma), the PKC inhibitor H7 (1.0 μg/ml; Sigma), the MEK inhibitor U0126 (10 μmol/L; Sigma), or the tyrosine kinase inhibitor genistein (10 μmol/L; Sigma) were added to the cultures 30 minutes before DEX (1000 nmol/L). After an incubation of 3 hours, the cells were harvested. To determine the CTGF mRNA stability of these DEX-treated cultured cells, those that had been incubated in the presence or absence of DEX (1000 nmol/L) for 3 hours were treated with the transcriptional inhibitor actinomycin-D (5 μg/ml; Sigma) for varying periods of time, after which they were harvested for RNA extraction. In a separate experiment, cells were harvested from collagenase-digested fragments of proximal tubules obtained from the cortices of both C57B6 and SJL mice using a modification of a previously described procedure.14Sheridan A Schwartz J Kroshian V Tercyak A Laraia J Masino S Lieberthal W Renal mouse proximal tubular cells are more susceptible than MDCK cells to chemical anoxia.Am J Physiol. 1993; 265: F323-F350PubMed Google Scholar Briefly, cortices were minced and incubated with 0.5 mg/ml of collagenase (type IV-S; Sigma) and 0.5 mg/ml of soybean trypsin inhibitor (Sigma) in Hanks' salt solution for 30 minutes at 37°C. After the large undigested fragments were removed by gravitation, the suspension was mixed with an equal volume of Hanks' solution containing 10% horse serum and centrifuged at 500 rpm for 7 minutes at room temperature. The pellets were washed once with Dulbecco's modified Eagle's medium by centrifugation, after which they were resuspended in the modified K-1 medium. Cells isolated using this technique were previously shown to be predominantly proximal tubular cells.14Sheridan A Schwartz J Kroshian V Tercyak A Laraia J Masino S Lieberthal W Renal mouse proximal tubular cells are more susceptible than MDCK cells to chemical anoxia.Am J Physiol. 1993; 265: F323-F350PubMed Google Scholar The response of these cells to DEX and rhTGF-β1 was determined as described above for the mProx24 and MCT cell lines. Animal care and treatment were provided in con-formity with institutional guidelines. Male C57B6, SJL, F1(C57B6xSJL), Balb/C, and 129 mice (5 to 7 weeks of age) were injected intraperitoneally with 1 mg of DEX in phosphate-buffered saline (PBS) per kg body weight; control mice were injected with PBS alone. These animals were then serially sacrificed after 1, 3, 12, 24, or 48 hours, and their kidneys, liver, and lungs were harvested and processed for RNA isolation and immunohistochemistry. Separate cohorts of C57B6 and SJL mice were injected intraperitoneally daily for 2 weeks with 1 mg/kg of DEX. We previously reported that when a given anti-sense oligodeoxynucleotide (ODN) was injected intravenously into rodents, it was absorbed into the proximal tubular epithelium where it was retained for nearly 48 hours and during which time it could block transcription of a target gene.7Okada H Kikuta T Kobayashi T Inoue T Kanno Y Takigawa M Sugaya T Kopp JB Suzuki H Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis.J Am Soc Nephrol. 2005; 16: 133-143Crossref PubMed Scopus (169) Google Scholar, 15Okada H Moriwaki K Kalluri R Imai H Ban S Takahama M Suzuki H Inhibition of monocyte chemoattractant protein-1 expression in tubular epithelium attenuates tubulointerstitial alteration in rat Goodpasture syndrome.Kidney Int. 2000; 57: 927-936Crossref PubMed Scopus (36) Google Scholar Thus, these mice were similarly injected intravenously with the CTGF anti-sense (5′-TGCGACGGAGGCGAGCAT-3′)7Okada H Kikuta T Kobayashi T Inoue T Kanno Y Takigawa M Sugaya T Kopp JB Suzuki H Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis.J Am Soc Nephrol. 2005; 16: 133-143Crossref PubMed Scopus (169) Google Scholar or mutated anti-sense ODNs (5′-TGCAGTGGAAATGAGTGC-3′) at a concentration of 1.0 mg/kg every 2 days from day 0 to day 14. The experimental groups consisted of C57B6 mice that were treated with DEX and anti-sense ODN (C57-AS, n = 8), C57B6 mice treated with DEX and mutated anti-sense ODN (C57-mAS, n = 8), SJL mice treated with DEX and anti-sense ODN (SJL-AS, n = 8), SJL mice treated with DEX and mutated anti-sense ODN (SJL-mAS, n = 8), and negative control mice of both strains (C57-NC, n = 8; SJL-NC, n = 8). After 12 hours or 2 weeks of treatment, the renal tissues from these animals were harvested for RNA extraction and immunohistochemistry. Twelve renal biopsy specimens from patients with minimal change nephrotic syndrome, six of whom had just received steroid pulse therapy (500 mg/24 hours of methyl-prednisolone for 3 days) and six who did not, were examined for the presence of CTGF. The specimens, all of which were confirmed cases of minimal change nephrotic syndrome, came from patients who underwent renal biopsy at our hospital between 1996 and 2002 for the evaluation of nephrotic range proteinuria. The protocol for the use of human materials was approved by the ethics committee of the institution. The specimens from these patients, as well as renal samples from the mice described above, were fixed in 4% paraformaldehyde overnight and processed for paraffin embedding. Sections (4 μm) were cut from these blocks, after which they were deparaffinized, rehydrated, and treated with proteinase K. The sections were then boiled in citrate buffer in a microwave to unmask antigenic sites. Endogenous biotin was blocked by using a biotin blocking system (X0590; DAKO Corp., Carpinteria, CA). The sections were then immersed in 3% H2O2 in methanol to inhibit endogenous peroxidase and incubated with 1% nonfat milk in PBS to block nonspecific binding. Rabbit polyclonal anti-CTGF (1:200) or anti-fibronectin (anti-FN; Life Technologies, Inc., Grand Island, NY) (1:400) primary antibodies were then applied to the sections, after which the sections were washed and then incubated with a biotin-conjugated anti-rabbit IgG secondary antibody. A catalyzed signal amplification system peroxidase (K1500; DAKO) was used to visualize the antibody reactions. Total RNA was extracted from the homogenates of kidney tissues and cultured cells using TRIzol (Life Technologies, Inc.) according to the manufacturer's instructions. All RNA samples were pretreated with RNase-free DNase I (Qiagen, Basel, Switzerland). The RT-PCR assay was performed to detect the expression of the glucocorticoid receptor gene using glucocorticoid receptor primers, forward 5′-CAAAGCCGTTTCACTGTCC-3′ and reverse 5′-ACAATTTCACACTGCCACC-3′.16Gupta V Wagner BJ Expression of the functional glucocorticoid receptor in mouse and human lens epithelial cells.Invest Ophthalmol Vis Sci. 2003; 44: 2041-2046Crossref PubMed Scopus (36) Google Scholar The PCR protocol was as follows: 94°C for 2 minutes, followed by 30 cycles at 94°C for 1 minute, 56°C for 1 minute, and 72°C for 1 minute, and ending with 72°C for 7 minutes. Real-time quantitative one-step RT-PCR assay was performed to quantify CTGF, TGF-β1, fibronectin EIIIA isoform (FN-EIIIA), α1 chain of type I procollagen (α1COLI), angiotensinogen, and GAPDH mRNAs using QuantiTect SYBR Green RT-PCR (Qiagen) and an ABI Prism 7700 sequence detection system (Applied Biosystems, Tokyo, Japan). The primers used for real-time RT-PCR were as follows: CTGF primers, forward 5′-GTGGAATATTGCCGGTGCA-3′, reverse 5′-CCATTGAAGCATCTTGGTTCG-3′; TGF-β1 primers, forward 5′-TCGTGGAACTGCCCTACCAG-3′, reverse 5′-ATGTTGGTGAGGGCGGAGAG-3′; FN-EIIIA primers, forward 5′-ATCCGGGAGCTTTTCCCTG-3′, reverse 5′-TGCAAGGCAACCACACTGAC-3′; α1COLI primers, forward 5′-TGTAAACTCCCTCCACCCCA-3′, reverse 5′-TCGTCTGTTTCCAGGGTTGG-3′; angiotensinogen primers, forward 5′-GAGGCAAATCTGAGCAACATTG-3′, reverse 5′-GAGTTCGAGGAGGATGCTATTGA-3′; and GAPDH primers, forward 5′-TGCAGTGGCAAAGTGGAGATT-3′, reverse 5′-TTGAATTTGCCGTGAGTGGA-3′. All of these oligonucleotides were designed by using Primer Express software (Perkin Elmer, Foster City, CA). Preliminary RT-PCR experiments in which these primer sets were used yielded appropriately sized, single products. A series of firefly luciferase reporter minigenes were constructed bearing various 5′ fragments of the CTGF gene. The plasmids, pCT-897.L, pCT-628.L, pCT-483.L, and pCT-202.L contained genomic DNA −897, −628, −483, and −202 bp upstream of the transcription start site, respectively. In these plasmids, genomic fragments were placed 5′ of the firefly luciferase cDNA in pGL3b (Promega, Madison, WI). The accuracy of all constructed plasmids was verified by sequencing. Transient transfections were performed using TransFast (Promega) according to the manufacturer's instructions. The Dual Luciferase system (Promega) was used for the sequential measurement of firefly and Renilla luciferase activity using the specific substrates of beetle luciferin and coelenterazine, respectively. One μg of pCT-897.L or isomolar amounts of other firefly luciferase constructs were co-transfected with 0.5 μg of Renilla luciferase control plasmid (pRL-TK; Promega) into 1.0 × 105 cells plated in each well of a six-well plate. The medium was changed 12 hours later, and the cells were incubated with or without 1000 nmol/L DEX in K-1 medium for another 36 hours. Quantification of luciferase activity and the calculation of relative ratios were performed manually using a luminometer (TD-20/20; Turner Designs, Sunnyvale, CA). The genomic sequences from −897 to −628 bp upstream of the transcription start site of the CTGF gene in C57B6 and SJL mice were determined using capillary sequence methods. Values are presented as the means ± SE. Statistical differences between groups were evaluated using a Bonferroni/Dunnett's test; P values that were ≤0.05 were considered to be statistically significant. Demographic data for the 12 patients whose biopsies were examined in this study are shown in Table 1. Although no CTGF protein expression was detected in the kidneys from the six untreated minimal change nephrotic syndrome patients (Figure 1A), CTGF protein localized in the tubular epithelial cells in four of the six kidney tissues from minimal change nephrotic syndrome patients who had been treated or who had just finished their treatment with steroid pulse therapy (Figure 1B). There were no differences in the demographic data between the CTGF-positive and -negative minimal change nephrotic syndrome patients (data not shown). In light of these findings, we next examined the effects of DEX on the expression of CTGF mRNA in the kidneys of different mouse strains. DEX treatment significantly increased CTGF mRNA levels in the kidneys of C57B6 mice (Figure 2A), had no effect in the kidneys of SJL mice (Figure 2B), and slightly increased CTGF mRNA levels in the kidneys of Balb/C and 129 mice (data not shown). Interestingly, DEX significantly increased CTGF mRNA levels in the lungs of C57B6 (4.3 ± 0.5-fold, P < 0.05) but not SJL mice after 3 hours. Regardless of DEX treatment, however, CTGF mRNA levels in the liver were significantly lower than those in the kidneys and lungs in both strains of mice. DEX slightly, but not significantly, increased CTGF mRNA levels in the kidneys of F1 (C57B6 × SJL) mice to levels that were approximately midway between the levels found in C57B6 and SJL mice (Figure 2C). Immunohistochemistry using an anti-CTGF antibody localized CTGF protein exclusively in the renal tubular epithelial cells of DEX-treated, but not untreated, C57B6 mice (Figure 2, D and E).Table 1Demographic Data of Patients with Minimal Change Nephrotic Syndrome at BiopsyCaseGender (M/F)AgePulse therapy (−/+)Oral PSL (mg/day)Proteinuria (mg/day)CTGF in TEC (−/+)1M23−03500−2M36−06200−3M28−04800−4M33−06800−5M40−09000−6F22−05500−7M17+508100−8F22+407900−9M23+609500+10M27+606800+11M27+605600+12F19+404500+Pulse therapy; methyl prednisolone 500 mg/day i.v. for 3 days, PSL, prednisolone; TEC, tubular epithelial cells. Open table in a new tab Figure 2DEX induction of CTGF expression in the mouse kidney. A: CTGF mRNA levels in DEX-treated C57B6 mice. B: CTGF mRNA levels in DEX-treated SJL mice. C: CTGF mRNA levels in DEX-treated F1 (C57B6 × SJL) mice. CTGF protein localization in the kidneys of DEX-treated C57B6 mice 24 hours after treatment (arrows) (D) and in the kidneys of untreated C57B6 mice (E). Each of the data in A, B, and C were obtained from four mice and data in D and E are representative of the sections from four mice in each case. DAB stain. Original magnifications, ×100.View Large Image Figure ViewerDownload Hi-res image Download (PPT) Pulse therapy; methyl prednisolone 500 mg/day i.v. for 3 days, PSL, prednisolone; TEC, tubular epithelial cells. The mProx24 and MCT tubular epithelial cell lines derived from C57B6 and SJL mice, respectively, were used to examine the effects of DEX on the induction of CTGF. RT-PCR revealed that both cell lines were positive for glucocorticoid receptor mRNA (Figure 3A). As expected from our in vivo findings, DEX increased CTGF mRNA levels in mProx24 cells in a dose-dependent manner (Figure 3B), with levels at 1 and 3 hours after DEX treatment being significantly greater than controls (Figure 3D). Because DEX facilitated CTGF mRNA degradation in mProx24 cells (Figure 3F), it was likely that this increase was attributable to the up-regulation of CTGF gene transcription by DEX. In contrast, DEX did not increase CTGF mRNA levels in MCT cells (Figure 3, C and E). Because DEX facilitated CTGF mRNA degradation in MCT cells to the same degree as in mProx24 cells (Figure 3G), it seems reasonable that DEX does not up-regulate CTGF gene transcription in MCT cells. These findings were unlikely to have been attributable to the spontaneous transformation of both cell lines in culture because DEX also significantly increased CTGF mRNA levels in primary cultured cells derived from C57B6, but not SJL, mice (Figure 3H). CTGF mRNA levels increased in both cell lines as well as both primary cultured cells in response to rhTGF-β1 (Figure 4), suggesting that they possessed the capacity to synthesize CTGF. DEX was reported to induce the expression of angiotensinogen and FN mRNA in certain cultured tubular epithelial cells.17Viedt C Bruger A Hansch GM Fibronectin synthesis in tubular epithelial cells: up-regulation of the EDA splice variant by transforming growth factor β.Kidney Int. 1995; 48: 1810-1817Crossref PubMed Scopus (46) Google Scholar, 18De Haij S Adcock IM Bakker AC Gobin SJ Daha MR van Kooten C Steroid responsiveness of renal epithelial cells. Dissociation of trans-repression and transactivation.J Biol Chem. 2003; 278: 5091-5098Crossref PubMed Scopus (19) Google Scholar We also found that DEX significantly increased angiotensinogen but not FN-EIIIA mRNA levels in both mProx24 and MCT cells (Figure 5, A–D), indicating that the glucocorticoid receptor binds to DEX and transduces signals into the nucleus to promote target transcription in both cell lines.Figure 4TGF-β1 induction of CTGF mRNA expression in mProx24 and MCT cells. Dose dependency of TGF-β1 induction of CTGF mRNA expression at 3 hours in mProx24 (A) and MCT cells (B). Time course of TGF-β1 (3 ng/ml) induction of CTGF mRNA expression in mProx24 (C) and MCT cells (D). E: Effect of TGF-β1 (3 ng/ml, 3 hours) on CTGF mRNA levels in the primary cultured cells derived from C57B6 and SLJ mice. The data in A to E were each obtained from four independent experiments.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 5DEX induction of mRNA expression of angiotensinogen and FN-EIIIA in mProx24 and MCT cells. DEX (1000 nmol/L) induction of angiotensinogen mRNA in mProx24 (A) and MCT cells (B). DEX (1000 nmol/L) induction of FN-EIIIA mRNA in mProx24 (C) and MCT cells (D). The data in A to D were each obtained from four independent experiments.View Large Image Figure ViewerDownload Hi-res image Download (PPT) The induction of CTGF mRNA expression by TGF-β1 was attenuated by tumor necrosis factor (TNF)-α in fibroblasts, an effect that was blocked by the PKC inhibitor Go6983, the MEK inhibitor U0126, and the tyrosine kinase inhibitor genistein in mesangial cells. DEX induction of CTGF mRNA expression was not affected by TNF-α or U0126, or by neutralizing anti-TGF-β or anti-CTGF antibodies (Figure 6). However, the PKC inhibitor H7 or genistein significantly attenuated DEX induction of CTGF mRNA expression in mProx24 cells (Figure 6), suggesting that PKC and tyrosine kinase pathways played a role in this process. GenBank data analysis revealed a number of consensus motifs in the promoter sequence of the mouse CTGF gene (representatives are shown in Figure 7A), although it was found to lack consensus glucocorticoid responsive cis-elements (GRE). Transient transfection experiments with firefly luciferase reporter constructs bearing CTGF promoter fragments revealed that there were universal positive and negative regulatory elements in the −483- to −202-bp and −628- to −483-bp fragments, respectively, elements that were not reactive to DEX (Figure 7, B and C). In contrast, the −897- to −628-bp fragment was found to contain positive regulatory elements that were responsive to DEX but were active only in mProx24, but not MCT, cells (Figure 7, B and C). We also identified two polymorphisms in the genomic DNA sequence of the −897- to −628-bp fragment between C57B6 and SJL mice (at −858 and −782 bp; Figure 7D) that were outside of the consensus motifs (ie, STAT3RE at −740 to −736 bp, and C/EBP at −688 to −676 bp). To determine the pathophysiological role of glucocorticoid in CTGF-mediated renal fibrogenesis, we treated glucocorticoid-susceptible (C57B6) and nonsusceptible (SJL) mice with DEX. Twelve hours after DEX treatment, both FN-EIIIA and CTGF mRNA levels were elevated in the kidneys of C57B6 mice (Figure 8B). Treatment of C57B6 mice with CTGF anti-sense ODN at the same time that they received DEX suppressed these elevations in both CTGF and FN-EIIIA mRNA levels (Figure 8A), supporting the notion that DEX-induced increases in CTGF mRNA levels indirectly resulted in elevations in FN-EIIIA mRNA levels. On the other hand, DEX treatment reduced CTGF and FN-EIIIA mRNA levels in SJL mice (Figure 8B). DEX treatment resulted in a significant induction in FN protein deposition in the kidneys of C57B6, but not SJL, mice 2 weeks after treatment (Figure 8D). DEX induction of CTGF expression in the mouse kidney was previously reported by Dammeier.11Dammeier J Beer HD Brauchle M Werner S Dexamethasone is a novel potent inducer of connective tissue growth factor expression.J Biol Chem. 1998; 273: 18185-18190Crossref PubMed Scopus (126) Google Scholar In our study, we found that tubular epithelial cells produced CTGF in response to DEX in vivo and in vitro. We also found the DEX-induced CTGF mRNA expression in the kidney is mouse strain-specific, with C57B6 mice responding to treatment in this way whereas SJL mice did not. A biopsy sample from a kidney of a minimal change nephrotic syndrome patient who had been treated with high doses of glucocorticoids revealed the presence of CTGF in tubular epithelial cells. This finding was not disease-specific because similar staining was demonstrated in the kidneys of glucocorticoid-treated lupus nephritis patients (data not shown). TGF-β1 is a strong inducer of CTGF in tubular epithelial cells8Inoue T Okada H Kobayashi T Watanabe Y Kanno Y Kopp JB Nishida T Takigawa M Ueno M Nakamura T Suzuki H Hepatocyte growth factor counteracts transforming growth factor-β1, through attenuation of connective tissue growth factor induction, and prevents renal fibrogenesis in 5/6 nephrectomized mice.FASEB J. 2003; 17: 268-270PubMed Google Scholar, 19Inoue T Okada H Kobayashi T Watanabe Y Kikuta T Kanno Y Takigawa M Suzuki H TGF-β1 and HGF coordinately facilitate collagen turnover in subepithelial mesenchyme.Bioche" @default.
• W2015607590 created "2016-06-24" @default.
• W2015607590 creator A5006703198 @default.
• W2015607590 creator A5009044898 @default.
• W2015607590 creator A5015247832 @default.
• W2015607590 creator A5015963255 @default.
• W2015607590 creator A5055796894 @default.
• W2015607590 creator A5078175026 @default.
• W2015607590 creator A5078649762 @default.
• W2015607590 creator A5086218037 @default.
• W2015607590 date "2006-03-01" @default.
• W2015607590 modified "2023-10-14" @default.
• W2015607590 title "Dexamethasone Induces Connective Tissue Growth Factor Expression in Renal Tubular Epithelial Cells in a Mouse Strain-Specific Manner" @default.
• W2015607590 cites W1528481919 @default.
• W2015607590 cites W1832979878 @default.
• W2015607590 cites W1984775628 @default.
• W2015607590 cites W1994069320 @default.
• W2015607590 cites W1999843107 @default.
• W2015607590 cites W2004751481 @default.
• W2015607590 cites W2005463323 @default.
• W2015607590 cites W2005566723 @default.
• W2015607590 cites W2025953637 @default.
• W2015607590 cites W2028934257 @default.
• W2015607590 cites W2038253791 @default.
• W2015607590 cites W2050959723 @default.
• W2015607590 cites W2055474522 @default.
• W2015607590 cites W2056813629 @default.
• W2015607590 cites W2057126191 @default.
• W2015607590 cites W2059466576 @default.
• W2015607590 cites W2061523453 @default.
• W2015607590 cites W2061927290 @default.
• W2015607590 cites W2072300954 @default.
• W2015607590 cites W2078840238 @default.
• W2015607590 cites W2087394026 @default.
• W2015607590 cites W2110997620 @default.
• W2015607590 cites W2111731443 @default.
• W2015607590 cites W2114329564 @default.
• W2015607590 cites W2120217387 @default.
• W2015607590 cites W2124168217 @default.
• W2015607590 cites W2126223232 @default.
• W2015607590 cites W2127801795 @default.
• W2015607590 cites W2128757614 @default.
• W2015607590 cites W2135664105 @default.
• W2015607590 cites W2145489141 @default.
• W2015607590 cites W2148244353 @default.
• W2015607590 cites W2160486758 @default.
• W2015607590 cites W2169970805 @default.
• W2015607590 cites W2171282302 @default.
• W2015607590 cites W2336339060 @default.
• W2015607590 doi "https://doi.org/10.2353/ajpath.2006.050656" @default.
• W2015607590 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1606512" @default.
• W2015607590 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16507889" @default.
• W2015607590 hasPublicationYear "2006" @default.
• W2015607590 type Work @default.
• W2015607590 sameAs 2015607590 @default.
• W2015607590 citedByCount "40" @default.
• W2015607590 countsByYear W20156075902012 @default.
• W2015607590 countsByYear W20156075902013 @default.
• W2015607590 countsByYear W20156075902015 @default.
• W2015607590 countsByYear W20156075902016 @default.
• W2015607590 countsByYear W20156075902017 @default.
• W2015607590 countsByYear W20156075902018 @default.
• W2015607590 countsByYear W20156075902019 @default.
• W2015607590 countsByYear W20156075902020 @default.
• W2015607590 countsByYear W20156075902021 @default.
• W2015607590 countsByYear W20156075902022 @default.
• W2015607590 countsByYear W20156075902023 @default.
• W2015607590 crossrefType "journal-article" @default.
• W2015607590 hasAuthorship W2015607590A5006703198 @default.
• W2015607590 hasAuthorship W2015607590A5009044898 @default.
• W2015607590 hasAuthorship W2015607590A5015247832 @default.
• W2015607590 hasAuthorship W2015607590A5015963255 @default.
• W2015607590 hasAuthorship W2015607590A5055796894 @default.
• W2015607590 hasAuthorship W2015607590A5078175026 @default.
• W2015607590 hasAuthorship W2015607590A5078649762 @default.
• W2015607590 hasAuthorship W2015607590A5086218037 @default.
• W2015607590 hasBestOaLocation W20156075901 @default.
• W2015607590 hasConcept C105702510 @default.
• W2015607590 hasConcept C134018914 @default.
• W2015607590 hasConcept C142724271 @default.
• W2015607590 hasConcept C170493617 @default.
• W2015607590 hasConcept C2775960820 @default.
• W2015607590 hasConcept C2778022156 @default.
• W2015607590 hasConcept C2780091579 @default.
• W2015607590 hasConcept C2780401358 @default.
• W2015607590 hasConcept C518705261 @default.
• W2015607590 hasConcept C529295009 @default.
• W2015607590 hasConcept C55493867 @default.
• W2015607590 hasConcept C71924100 @default.
• W2015607590 hasConcept C86803240 @default.
• W2015607590 hasConcept C95444343 @default.
• W2015607590 hasConceptScore W2015607590C105702510 @default.
• W2015607590 hasConceptScore W2015607590C134018914 @default.
• W2015607590 hasConceptScore W2015607590C142724271 @default.
• W2015607590 hasConceptScore W2015607590C170493617 @default.
• W2015607590 hasConceptScore W2015607590C2775960820 @default.
• W2015607590 hasConceptScore W2015607590C2778022156 @default.
• W2015607590 hasConceptScore W2015607590C2780091579 @default.

• next